This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Keryx: Readers React to Perifosine Prediction

Stocks in this article: KERX AEZS

Fariba G. asks, "Interesting analysis of microcap stock and trial outcome. Was the bearish view of Dr. Ratain based on this statistics or did he bring scientific backing for his view?"

"Finland64" emails, "It would be great if you could take some time to write that article on the flaws (and perhaps the strengths) in the perifosine phase II colon cancer trial…Would it also be possible for you to include the fact that it was a controlled, randomized, double blinded study?"

The strongest, most reliable, clinical data comes from randomized, controlled studies. No disagreement there. I've long criticized biotech companies that run crappy single-arm phase II studies and then make dubious survival-benefit claims based on comparisons to outdated "historical" data. Blech.

Ratain has also been a vocal proponent of randomized studies and believes the high failure rate in cancer drug development stems, in large part, from the over-reliance on single-arm trial designs.

As he says above, Ratain also believes the perifosine phase II study is flawed, despite what looks to be a randomized, controlled clinical trial design.

As originally conducted, the phase II study was designed to determine perifosine's signal of activity. Initially, 381 patients diagnosed with seven different types of cancer and treated with eight separate chemotherapy regimens were to be enrolled in the study. Within each tumor type, patients were to be treated with either perifosine or a placebo.

Full enrollment in the study never took place. Instead, an unplanned interim analysis was conducted which revealed evidence of clinical activity when perifosine was combined with capecitabine (sold by Roche under the brand name Xeloda) in 25 colon cancer patients. Based on this unplanned analysis, the original study design was abandoned and instead, an additional 13 colon cancer patients were enrolled in the study to bring the total number of colon cancer patients to 38.

It's data from these 38 colon cancer patients -- which again, purports to show a survival benefit favoring the perifosine-capecitabine combination over capecitabine alone -- that Keryx relied upon to design the ongoing phase III study.

3 of 7

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,804.80 +26.65 0.15%
S&P 500 2,070.65 +9.42 0.46%
NASDAQ 4,765.38 +16.9840 0.36%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs